The “two-hit” storm: a hyper-inflammatory endotype in pediatric long COVID and its role in the severity of secondary bacterial pneumonia—a mechanistic review and clinical implications
Authors:
Open Access
- 20 April 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1782871
Abstract
Following the COVID-19 pandemic, the clinical patterns of pediatric respiratory infections have undergone significant changes, with increasing attention on the immunological imprint left by Post-Acute Sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID. A perplexing clinical phenomenon has been observed: some children with a history of Long COVID exhibit a disproportionately severe inflammatory response and extensive lung injury when encountering common community-acquired pneumonia, such as that caused by Mycoplasma pneumoniae or Streptococcus pneumoniae , inconsistent with their pathogen load. This review aims to dissect this phenomenon and proposes the “Immune Priming and Two-Hit” model as its core pathophysiological framework. This model posits that the Long COVID state constitutes the “first hit,” establishing a “primed” or “hyper-reactive” immune baseline through viral persistence, trained immunity-induced monocyte reprogramming, and sustained endothelial dysfunction. Upon the “second hit” of a bacterial infection, this primed immune system triggers a dysregulated, synergistically amplified inflammatory cascade. The mechanisms involve the exponential release of cytokines such as Interleukin-6 (IL-6), IL-1β, and Tumor Necrosis Factor- α (TNF-α), inflammation-mediated immunothrombosis, and excessive activation of Neutrophil Extracellular Trap formation (NETosis), ultimately leading to severe outcomes like Acute Respiratory Distress Syndrome (ARDS) and necrotizing pneumonia. Consequently, identifying and defining this “Hyper-inflammatory endotype” is of critical clinical importance. We define it as an “endotype” to emphasize the distinct, host-determined pathophysiological mechanisms underlying it, rather than merely a collection of clinical manifestations. By monitoring biomarkers such as ferritin, D-dimer, lactate dehydrogenase (LDH), and lymphocyte counts, clinicians may be able to perform early risk stratification of these children. This approach not only facilitates a shift in therapeutic strategy from purely antimicrobial therapy to “host-directed therapy”—emphasizing the necessity of early, adequate corticosteroid use and consideration of anticoagulation—but also provides a new theoretical basis and intervention window for preventing long-term sequelae such as pulmonary fibrosis.Keywords
This publication has 37 references indexed in Scilit:
- Lingering echoes of SARS-CoV-2: mechanistic insights and management of long COVID syndromeInflammopharmacology, 2025
- Seven days versus extended duration antibiotic therapy for multidrug-resistant gram-negative bacterial infections in critically ill patients: A pooled analysis of the OPTIMISE and REGARD-VAP trialsJournal of Critical Care, 2025
- Development and validation of an interpretable machine learning model using routine laboratory biomarkers to stratify severe pneumonia risk in young childrenJournal of Advanced Research, 2025
- Targeting TLR7 reprograms macrophage function to attenuate influenza-associated Staphylococcus aureus coinfectionMicrobial Pathogenesis, 2025
- Effect of dynamic neuromuscular stabilization exercises on postural stability, pulmonary function, motor performance, and quality of life in post-COVID-19 patients: A randomized controlled trialJournal of Bodywork and Movement Therapies, 2025
- Antiviral innate immune memory in alveolar macrophages following SARS-CoV-2 infection ameliorates secondary influenza A virus diseaseImmunity, 2024
- Epigenetic memory of coronavirus infection in innate immune cells and their progenitorsCell, 2023
- Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responsesThe Lancet Respiratory Medicine, 2021
- Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in childrenIntensive Care Medicine, 2020
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006